Aktuellt
SENASTE
Redeye saw a report where the first sales were reported for Terclara, and the cost aligned with expectations. The EBITDA level was in line with expectations, and the processes are in line with what has been communicated earlier, with a strong focus on the current phase 3 study in the US and securing further Terbinafine for upcoming launches. We do not expect significant changes to our estimates, although a revision of the expected amount from the TO could be warranted.
LÄS MER
